Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension

Figures & data

Table I. Doxazosin in the treatment of resistant arterial hypertension.

Number of patients (females)	97 (44)
Age, years	59 ± 9.5
Blood pressure, mmHg, n = 97
Before the initiation of doxazosin	167 ± 30/95 ± 18
End of follow-up period	136 ± 28/78 ± 17
Number of antihypertensive drugs, including doxazosin	5.2 ± 0.8
Duration of doxazosin treatment (months)	21 ± 17
Mean doxazosin dose (mg/day)	8.5 ± 5.4
Numbers of patients using various doses of doxazosin
2 mg/day (n)	18
4 mg/day (n)	23
8 mg/day (n)	22
12 mg/day (n)	7
16 mg/day (n)	27

Unless stated otherwise, data are given as means and standard deviations. n, the number of patients.

Figure 1. Blood pressure changes in both the entire group and the efficacy analysis subgroup (i.e. the patients in whom there was no change in the concomitant medication regimen following the initiation of doxazosin(. SBP, systolic blood pressure; DBP, diastolic blood pressure.